United Therapeutics’ Once-Daily Pill Cuts Clinical Worsening in PAH by 55%
United Therapeutics' ralinepag reduced clinical worsening risk by 55% in PAH phase 3 study. Once-daily oral drug shows strong efficacy; FDA filing planned for 2026.
/ 3 items
#UTHR↓
United Therapeutics Unveils Tresmi: The "Category Killer" Inhaler Set to End Coughing Woes in PAH and ILD
United Therapeutics announces Tresmi, a revolutionary soft mist inhaler version of Treprostinil that cuts coughing side effects by up to 90%. Planned approval filing this year and launch next year, impacting strategic partner MannKind's stock.
A Breath of Fresh Air: Tyvaso Offers New Hope for Idiopathic Pulmonary Fibrosis
United Therapeutics' Tyvaso Inhalation Solution demonstrates significant benefits in the TETON-2 study for Idiopathic Pulmonary Fibrosis (IPF), offering new hope and potential treatment advancements for this debilitating lung condition.